4 Reasons to Buy Medtronic Stock Like There's No Tomorrow

Medtronic reported fiscal 2026 revenue growth of 8.4% to $36.4B (5.8% organic), led by 9.3% organic cardiovascular growth (+38%+ of enterprise revenue). Free cash flow rose 4.6% to $5.43B, with only $3.64B spent on dividends, supporting continued payout growth (forward yield 3.1% and 49 straight years of increases). Management targets fiscal 2027 organic revenue growth of 7.25%–7.75%, and the stock at ~$92 trades at 18x next year’s EPS versus 21x for the S&P 500—framing the update as a valuation re-rate opportunity alongside improving fundamentals.

Analysis

MDT is shifting from a "safe income" name to a self-help rerating story, and the market will care more about operating leverage than the dividend label. In a large-cap device platform, sustained mid-to-high single-digit organic growth can translate into outsized EPS upside if restructuring keeps fixed-cost absorption improving; that is the real catalyst for multiple expansion, not the yield itself. Over the next 1-3 quarters, the stock should trade on whether the cardiovascular engine is proving durable enough to reset expectations for the whole portfolio.

The competitive read-through is that BSX and ABT are now under a higher bar in the cardiovascular and adjacent cardiac subsegments: if MDT is regaining relevance, it becomes harder for focused peers to justify premium multiples purely on "better growth". MMED is the second-order loser because a standalone diabetes asset loses the conglomerate scale and cash-flow cushion that supported the parent valuation. That creates a potential value gap trade if the spin-off remains under-earnings-power pressure.

Contrarian risk: the market may be over-crediting the durability of the acceleration if it is partly backlog normalization, mix shift, or commercial intensity rather than a true demand inflection. The thesis is strongest over 6-18 months if MDT can string together two more quarters of >6% organic growth with stable margins; it breaks quickly if growth slips back toward low-single digits or any quality/regulatory issue reappears. In that case, the "cheap" multiple is likely just the right multiple for a slow-growing medtech conglomerate.

Key Decisions for Investors

• Initiate a 6-12 month long MDT position on pullbacks, targeting a rerating toward low-20s forward earnings if organic growth holds; use a thesis stop if next two quarters fall below ~6% organic growth or margin expansion stalls.
• Pair trade: long MDT / short XLV or IHI for 3-6 months to express relative re-rating in medtech self-help versus the broader healthcare complex; target modest spread capture rather than a home-run move.
• For event-driven accounts, buy MDT Jan-2027 90/105 call spreads to express upside with defined risk; the trade works if investors start capitalizing the dividend plus growth inflection as a higher-quality compounding profile.
• Watch MMED as a potential short or avoid list item until standalone cash generation is visible; the missing data point is whether it can sustain margins without the parent scale, which will determine whether the spin is a value unlock or a drag.